A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) | MicrobiomeTrials← Back to trialsNCT07744152
A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-09-21Est. Completion: 2030-01-15
Enrollment target: 137 participants Locations- UZ Leuven, Leuven, Belgium
- Beijing Cancer Hospital, Beijing, China
- Shanghai East Hospital, Shanghai, China
- Technische Universität Dresden, Dresden, Germany
- Klinikum der Universität München AÖR, München, Germany
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Amsterdam (METC AVL), Amsterdam, Netherlands
- Hospital del Mar, Barcelona, Spain
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Clínica Universidad de Navarra, Navarra, Spain
- Hospital Clinico Universitario de Valencia, Valencia, Spain
Other microbiome trials you might be interested in
Colorectal NeoplasmsNeoplasmsIntrahepatic CholangiocarcinomaAdrenocortical CarcinomaMetastasis, Neoplasm
Background:
Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …
Bethesda, United StatesEst. completion Dec 31, 2029
Non-small Cell Lung CancerNSCLC
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed …
Little Rock, United StatesEst. completion Jan 12, 2029
Carcinoma, Non-Small-Cell Lung
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet…
Birmingham, United StatesEst. completion Sep 7, 2029